SCHEMBL15416397

SCHEMBL15416397

CS(=O)(=O)CCn1c(CO)nc2ccccc21

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.61
LMNA P02545 4/20 0.60
KMT2A Q03164 2/20 0.60
KDM4E B2RXH2 1/20 0.60
SMN1; SMN2 Q16637 4/20 0.54
RAB9A P51151 3/20 0.54
TP53 P04637 2/20 0.54
NPC1 O15118 1/20 0.54
MAPK1 P28482 2/20 0.54
MEN1 O00255 1/20 0.53
ALDH1A1 P00352 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
TSHR P16473 2/20 0.49
TNF P01375 1/20 0.49
USP2 O75604 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C19 P33261 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7745194 0.92 SMN1; SMN2 (0.59) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL15416721 0.86 KMT2A (0.56) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL1520364 0.80 POLB (0.69) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL1520195 0.80 POLB (0.73) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL5858779 0.79 SLC9A1 (0.46) LMNAKMT2ASMN1; SMN2TP53MAPK1
SCHEMBL7740722 0.78 MEN1 (0.54) POLBLMNAKMT2ASMN1; SMN2TP53
SCHEMBL2017366 0.77 POLB (0.64) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL4897865 0.77 LMNA (0.71) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL1520593 0.77 SMN1; SMN2 (0.64) POLBLMNAKMT2AKDM4ESMN1; SMN2
SCHEMBL7740380 0.77 MAPK1 (0.76) POLBLMNAKMT2AKDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2872502-B1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION HOFFMANN LA ROCHE (CH) 2016-08-24 EP disclosed
US-20160200741-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2016-07-14 US disclosed
US-9206191-B2 Indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2015-12-08 US disclosed
US-20150158879-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection HOFFMANN-LA ROCHE INC. (US) 2015-06-11 US disclosed
EP-2872502-A1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. Hoffmann-La Roche AG (CH) 2015-05-20 EP disclosed
WO-2014009302-A1 NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150158879-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection ADORA3, ADORA1, BRS3 POLB 3431/4885LMNA 1712/4885KMT2A 2954/4885
US-20160200741-A1 Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection ADORA3, ADORA1, BRS3 POLB 3431/4885LMNA 1712/4885KMT2A 2954/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.